KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Tax Provisions (2018 - 2025)

Historic Tax Provisions for Xenon Pharmaceuticals (XENE) over the last 8 years, with Q3 2025 value amounting to $677000.0.

  • Xenon Pharmaceuticals' Tax Provisions rose 31156.25% to $677000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 133183.86%. This contributed to the annual value of $4.8 million for FY2024, which is 173527.4% up from last year.
  • Xenon Pharmaceuticals' Tax Provisions amounted to $677000.0 in Q3 2025, which was up 31156.25% from -$626000.0 recorded in Q2 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Tax Provisions peaked at $5.0 million during Q4 2024, and registered a low of -$626000.0 during Q2 2025.
  • Moreover, its 5-year median value for Tax Provisions was -$157000.0 (2023), whereas its average is $269315.8.
  • The largest annual percentage gain for Xenon Pharmaceuticals' Tax Provisions in the last 5 years was 355714.29% (2021), contrasted with its biggest fall of 670000.0% (2021).
  • Xenon Pharmaceuticals' Tax Provisions (Quarter) stood at $484000.0 in 2021, then surged by 144.42% to $1.2 million in 2022, then tumbled by 117.33% to -$205000.0 in 2023, then skyrocketed by 2546.83% to $5.0 million in 2024, then crashed by 86.5% to $677000.0 in 2025.
  • Its last three reported values are $677000.0 in Q3 2025, -$626000.0 for Q2 2025, and $427000.0 during Q1 2025.